ClinicalTrials.gg
CompletedNCT04101721BUTTERFLEYEUpdated Jul 20, 2023Results posted

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

A Phase 3 interventional study of aflibercept and laser photocoagulation in Retinopathy of Prematurity, sponsored by Regeneron Pharmaceuticals. Completed at 52 sites in 13 countries. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
127
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Retinopathy of Prematurity with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Retinopathy of Prematurity · United States.

Enrollment
13th of 32
127 · median 114
Started
2019
with 1 other
Phase 3
8 of 51
none open now
Registered
36th of 51
by date
Lead sponsor
2 of 51
Regeneron Pharmaceuticals

Among the 51 studies in Retinopathy of Prematurity with a site in United States, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2019, is one of 8 in phase 3, and was the 36th registered.

Retinopathy of Prematurity

169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.

Browse Retinopathy of Prematurity studies →

Open to participants now

6 of the 51 studies in Retinopathy of Prematurity with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Retinopathy of Prematurity studies recruiting now, 7 (37%) set no upper age limit and 12 (63%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Retinopathy of Prematurity with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the efficacy of aflibercept compared to laser in patients diagnosed with retinopathy of prematurity (ROP). The secondary objectives of the study are to assess the need for a second treatment modality, to assess the recurrence of ROP in the study and to assess the safety and tolerability of aflibercept.

03

Conditions studied

  • Retinopathy of Prematurity
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Gestational age at birth ≤ 32 weeks or birth weight ≤1500 g
  • Patients with treatment-naïve retinopathy of prematurity (ROP) classified according to the International Classification for ROP in at least one eye as:

    • Zone I Stage 1 plus, or 2 plus, or 3 non-plus or 3 plus, or
    • Zone II Stage 2 plus or 3 plus, or
    • Aggressive posterior retinopathy of prematurity (AP-ROP)

Key Exclusion Criteria:

  • Known or suspected chromosomal abnormality, genetic disorder, or syndrome
  • Previous exposure to any Intravitreal (IVT) or systemic anti-vascular endothelial growth factor (VEGF) agent, including maternal exposure during pregnancy and/or during breastfeeding
  • neurological disease (eg, intraventricular hemorrhage grade 3 or higher, periventricular leukomalacia, congenital brain lesions significantly impairing optic nerve function, severe hydrocephalus with significantly increased intracranial pressure)
  • Pediatric conditions rendering the infant ineligible for study intervention at baseline or for repeated blood draws as evaluated by a neonatal intensive care unit specialist and a study ophthalmologist
  • Presence of active ocular infection within 5 days of the first treatment
  • Advanced stages of ROP with partial or complete retinal detachment (ROP stage 4 and stage 5)
  • ROP involving only Zone III

NOTE: Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Aflibercept Group

    Patients will receive a single intravitreal (IVT) injection per eligible eye at baseline.

    Drug: aflibercept

  • Experimental
    Laser Group

    Patients will undergo laser treatment in each eligible eye at baseline.

    Procedure: laser photocoagulation

Interventions

  • Administered IVT

    Also known as: EYLEA®, REGN3, VEGF trap-eye, BAY86-5321

  • Procedurelaser photocoagulation

    Transpupillary conventional laser will be administered according to standard local procedures.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age

    Active ROP was ROP requiring treatment and unfavorable structural outcome was defined as retinal detachment, macular dragging, macular fold, or retrolental opacity. For participants with both eyes enrolled in the study, both eyes must have met the endpoint. Participants with only one study eye enrolled were responders if the respective eye responded.

    Time frame: Baseline to week 52 of chronological age

Secondary outcomes

  1. Percentage of Participants Requiring Intervention With a Second Treatment Modality From Baseline to Week 52 of Chronological Age

    Second treatment modality includes any treatment in addition to that assigned to the participant at baseline. This includes per-protocol rescue treatment (laser for aflibercept group, aflibercept for laser group), anti-VEGF agents not part of study protocol (e.g., bevacizumab, ranibizumab, commercially-available aflibercept not provided as study medication), or any ocular surgery for the management of any retinal pathology secondary to ROP (e.g., victrectomy, scleral buckle for retinal detachments).

    Time frame: Baseline to to week 52 of chronological age

  2. Percentage of Participants With Recurrence of ROP Through Week 52 of Chronological Age

    Recurrence of disease is defined as the reappearance of the disease requiring further treatment (including retreatment or rescue), where both "presence of ROP" and "presence of active ROP requiring treatment" are marked as "Yes", after initial regression. Here, the initial regression is defined as, at a particular visit, absence of ROP or ROP treatment not required for active ROP, i.e., presence of ROP is marked as "No" or the presence of active ROP requiring treatment is marked as "No."

    Time frame: Baseline to week 52 of chronological age

  3. Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Time frame: Baseline to Week 52 of chronological age

  4. Percentage of Participants With Systematic (Non-ocular) TEAEs and TESAEs

    Time frame: Baseline to Week 52 of chronological age

07

Results

Posted Jul 20, 2023

Participant flow

137 participants were screened, 127 were randomized.

Participant flow — Overall Study
MilestoneLaser PhotocoagulationAflibercept 0.4 mg
Started2793
Completed2687
Not completed16
Withdrew: Withdrawal by parent/guardian12
Withdrew: Death01
Withdrew: Lost to follow-up03

Outcome measures

PrimaryPercentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age

Active ROP was ROP requiring treatment and unfavorable structural outcome was defined as retinal detachment, macular dragging, macular fold, or retrolental opacity. For participants with both eyes enrolled in the study, both eyes must have met the endpoint. Participants with only one study eye enrolled were responders if the respective eye responded.

Time frame:
Baseline to week 52 of chronological age
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age
Percentage of participantsLaser PhotocoagulationAflibercept 0.4 mg
Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age77.879.6
Statistical analysis
  • Laser Photocoagulation vs Aflibercept 0.4 mg · Adjusted difference: 1.81 · 95.1% CI -15.71 to 19.33
SecondaryPercentage of Participants Requiring Intervention With a Second Treatment Modality From Baseline to Week 52 of Chronological Age

Second treatment modality includes any treatment in addition to that assigned to the participant at baseline. This includes per-protocol rescue treatment (laser for aflibercept group, aflibercept for laser group), anti-VEGF agents not part of study protocol (e.g., bevacizumab, ranibizumab, commercially-available aflibercept not provided as study medication), or any ocular surgery for the management of any retinal pathology secondary to ROP (e.g., victrectomy, scleral buckle for retinal detachments).

Time frame:
Baseline to to week 52 of chronological age
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring Intervention With a Second Treatment Modality From Baseline to Week 52 of Chronological Age
Percentage of participantsLaser PhotocoagulationAflibercept 0.4 mg
Percentage of Participants Requiring Intervention With a Second Treatment Modality From Baseline to Week 52 of Chronological Age18.515.1
Statistical analysis
  • Laser Photocoagulation vs Aflibercept 0.4 mg · Adjusted difference: -3.66 · 95.1% CI -19.86 to 12.54
SecondaryPercentage of Participants With Recurrence of ROP Through Week 52 of Chronological Age

Recurrence of disease is defined as the reappearance of the disease requiring further treatment (including retreatment or rescue), where both "presence of ROP" and "presence of active ROP requiring treatment" are marked as "Yes", after initial regression. Here, the initial regression is defined as, at a particular visit, absence of ROP or ROP treatment not required for active ROP, i.e., presence of ROP is marked as "No" or the presence of active ROP requiring treatment is marked as "No."

Time frame:
Baseline to week 52 of chronological age
Reported as:
Number · Percentage of participants
Percentage of Participants With Recurrence of ROP Through Week 52 of Chronological Age
Percentage of participantsLaser PhotocoagulationAflibercept 0.4 mg
Percentage of Participants With Recurrence of ROP Through Week 52 of Chronological Age29.639.8
Statistical analysis
  • Laser Photocoagulation vs Aflibercept 0.4 mg · Adjusted difference: 10.10 · 95.1% CI -9.83 to 30.02
SecondaryPercentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time frame:
Baseline to Week 52 of chronological age
Reported as:
Number · Percentage of participants
Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Percentage of participantsLaser PhotocoagulationAflibercept 0.4 mg
% Ocular TEAEs25.918.3
% Ocular TESAEs11.16.5
SecondaryPercentage of Participants With Systematic (Non-ocular) TEAEs and TESAEs
Time frame:
Baseline to Week 52 of chronological age
Reported as:
Number · Percentage of participants
Percentage of Participants With Systematic (Non-ocular) TEAEs and TESAEs
Percentage of participantsLaser PhotocoagulationAflibercept 0.4 mg
% Systematic TEAEs51.947.3
% Systematic TESAEs7.412.9

Adverse events

Collected over From signing of informed consent form (ICF) to end of study (week 52 of chronological age visit), an average of 42 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Laser Photocoagulation0/27 (0%)12/27 (44.4%)12/27 (44.4%)
Aflibercept 0.4 mg1/93 (1.1%)32/93 (34.4%)40/93 (43%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventLaser PhotocoagulationAflibercept 0.4 mg
ApnoeaRespiratory, thoracic and mediastinal disorders2/272/93
Retinal detachment Study EyeEye disorders2/276/93
BronchiolitisInfections and infestations1/272/93
PneumoniaInfections and infestations1/271/93
Pneumonia viralInfections and infestations1/271/93
Apnoeic attackRespiratory, thoracic and mediastinal disorders1/270/93
AspirationRespiratory, thoracic and mediastinal disorders1/270/93
Chronic respiratory diseaseRespiratory, thoracic and mediastinal disorders1/270/93
Inguinal herniaGastrointestinal disorders1/272/93
Gastrooesophageal reflux diseaseGastrointestinal disorders1/270/93
Most frequent other events
Showing 10 of 16
Most frequent other events
EventLaser PhotocoagulationAflibercept 0.4 mg
ConstipationGastrointestinal disorders4/274/93
PyrexiaGeneral disorders4/274/93
Inguinal herniaGastrointestinal disorders3/274/93
Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders0/277/93
Gastrooesophageal reflux diseaseGastrointestinal disorders2/275/93
Bacterial disease carrierInfections and infestations2/271/93
OsteopeniaMusculoskeletal and connective tissue disorders2/272/93
ApnoeaRespiratory, thoracic and mediastinal disorders2/271/93
CoughRespiratory, thoracic and mediastinal disorders2/273/93
WheezingRespiratory, thoracic and mediastinal disorders2/271/93

Baseline characteristics

Full analysis set (FAS): All randomized participants who received any study treatment. Eyes analyzed includes all treated eyes.

Age, Continuous
Age, Continuous(Weeks)Laser PhotocoagulationAflibercept 0.4 mgTotal
Mean11.09 ± 4.3389.76 ± 3.14910.06 ± 3.476
Sex: Female, Male
Sex: Female, Male(Participants)Laser PhotocoagulationAflibercept 0.4 mgTotal
Female105262
Male174158
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Laser PhotocoagulationAflibercept 0.4 mgTotal
Hispanic or Latino41620
Not Hispanic or Latino227294
Unknown or Not Reported156
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Laser PhotocoagulationAflibercept 0.4 mgTotal
White112637
Black or African American268
Asian134457
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Other11213
Not Reported055
Retinopathy of prematurity (ROP) Zone, by eye
Retinopathy of prematurity (ROP) Zone, by eye(Eyes)Laser PhotocoagulationAflibercept 0.4 mgTotal
Zone I134760
Zone II37132169
08

Study locations

52 sites
  • Regeneron Study Site
    Phoenix, Arizona 85016, United States
  • Regeneron Study Site
    La Jolla, California 92093, United States
  • Regeneron Study Site
    Loma Linda, California 92354, United States
  • Regeneron Study Site
    Orange, California 92868, United States
  • Regeneron Study Site
    Palo Alto, California 94303, United States
  • Regeneron Study Site
    San Diego, California 92123, United States
  • Regeneron Study Site
    San Francisco, California 94143, United States
  • Regeneron Study Site
    Gainesville, Florida 32608, United States
  • Regeneron Study Site
    Augusta, Georgia 78705, United States
  • Regeneron Study Site
    Chicago, Illinois 60612, United States
  • Regeneron Study Site
    Boston, Massachusetts 02111, United States
  • Regeneron Study Site
    Ann Arbor, Michigan 48105, United States
  • Regeneron Study Site
    Royal Oak, Michigan 48073, United States
  • Regeneron Study Site
    Bronx, New York 10462, United States
  • Regeneron Study Site
    Brooklyn, New York 11203, United States
  • Regeneron Study Site
    Brooklyn, New York 11213, United States
  • Regeneron Study Site
    Buffalo, New York 14209, United States
  • Regeneron Study Site
    New York, New York 10017, United States
  • Regeneron Study Site
    New York, New York 10029, United States
  • Regeneron Study Site
    Valhalla, New York 10595, United States
  • Regeneron Study Site
    Cleveland, Ohio 44106, United States
  • Regeneron Study Site
    Oklahoma City, Oklahoma 73104, United States
  • Regeneron Study Site
    Providence, Rhode Island 02905, United States
  • Regeneron Study Site
    Austin, Texas 78705, United States
  • Regeneron Study Site
    San Antonio, Texas 78229, United States
  • Regeneron Study Site
    San Antonio, Texas 78240, United States
  • Regeneron Study Site
    Morgantown, West Virginia 26506, United States
  • Regeneron Study Site
    Sofia, 1407, Bulgaria
  • Regeneron Study Site
    Sofia, 1504, Bulgaria
  • Regeneron Study Site
    Varna, 9002, Bulgaria
  • Regeneron Study Site
    Medellin, Antioquia 50034, Colombia
  • Regeneron Study Site
    Floridablanca, Santander 681004, Colombia
  • Regeneron Study Site
    Ostrava-Poruba, 708 52, Czechia
  • Regeneron Study Site
    Debrecen, H-4032, Hungary
  • Regeneron Study Site
    Cheonan, 31151, Korea, Republic of
  • Regeneron Study Site
    Iași, 700038, Romania
  • Regeneron Study Site
    Saint-Petersburg, Sankt-Peterburg 194100, Russian Federation
  • Regeneron Study Site
    Moscow, 119571, Russian Federation
  • Regeneron Study Site
    Moscow, 119620, Russian Federation
  • Regeneron Study Site
    Bratislava, 833 40, Slovakia
  • Regeneron Study Site
    Kaohsiung, 81346, Taiwan
  • Regeneron Study Site
    Pathum Wan, Bangkok 10330, Thailand
  • Regeneron Study Site
    Ratchathewi, Bangkok 10400, Thailand
  • Regeneron Study Site
    Chiangmai, Chiang Mai 50200, Thailand
  • Regeneron Study Site
    Hat Yai, Songkhla 90110, Thailand
  • Regeneron Study Site
    Khon Kaen, 40002, Thailand
  • Regeneron Study Site
    Adana, 4522, Turkey
  • Regeneron Study Site
    Ankara, 06100, Turkey
  • Regeneron Study Site
    Ankara, 06560, Turkey
  • Regeneron Study Site
    Eskisehir, 26480, Turkey
  • Regeneron Study Site
    Ho Chi Minh, 70000, Vietnam
  • Regeneron Study Site
    Hue, 100000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Aug 2022, 33 months.

Results were first posted in Jul 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 24, 2019
StartActual
Oct 30, 2019
Primary completionActual
Aug 18, 2022
CompletionActual
Aug 18, 2022
Results first posted
Jul 20, 2023
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04101721
Responsible party
Sponsor
First posted
Sep 24, 2019
Start date
Oct 30, 2019
Primary completion
Aug 18, 2022
Completion
Aug 18, 2022
Results posted
Jul 20, 2023
Last update
Jul 20, 2023

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion